Enhanced funding significantly impacts clinical trials by enabling the enrollment of more participants, expanding the scope of studies, and improving the overall quality of data collected. This can lead to more robust and reliable results, ultimately accelerating the approval and availability of new treatments. Additionally, increased funding allows for the exploration of rare cancer types that might otherwise be neglected due to limited financial resources.
